

MOST Market Roundup



Market Update

Nifty : 25,574.35 +82.05 (+0.32%) Sensex : 83,535.35 +319.07 (+0.38%)

- Equity benchmarks ended higher, with the Sensex climbing over 300 points and the Nifty reclaiming the 25,550 mark, supported by a rally in global markets. Investor sentiment improved on expectations of an end to the prolonged U.S. government shutdown and optimism over a robust corporate earnings season. Positive cues also came from hopes of progress in the U.S.-India trade deal and strong domestic economic indicators.
- Buying was seen across IT, metal, sugar, select pharma, and defense stocks. The Sensex advanced 319 points, or 0.40%, to close at 83,535, while the Nifty gained 82 points, or 0.30%, to settle at 25,574.
- Globally, U.S. index futures rose over 1%, while Asian and European markets gained up to 1%, driven by a rebound in technology shares following last week's selloff on valuation concerns. Optimism around a resolution to the U.S. government shutdown further boosted sentiment.
- The Nifty IT Index surged 1.5%, led by Infosys, HCL Tech, LTI Mindtree, and TCS, following strong quarterly results and gains in the Nasdaq Futures. Defense stocks also witnessed renewed buying interest after HAL signed a major deal with General Electric (GE), USA, for the supply of 113 F404-GE-IN20 engines and related support packages for 97 LCA Mk1A aircraft. HAL shares jumped 3.5% to close at ₹4,790, while the Nifty Defense Index advanced 1.2%.
- In the metal space, the Nifty Metal Index rose 0.6% after National Aluminium Company (Nalco) reported strong Q2 results. Nalco shares surged 10% to ₹257 with heavy trading volumes of 7.27 crore shares on the NSE.

Technical Outlook:

- Nifty index opened on a positive note and moved upwards beyond 25650 zones. It witnessed some consolidation in the second half of the session but support levels were intact. Throughout the session it maintained the upside trajectory with advances outpacing declines.
- It formed a bullish candle on the daily frame and negated its lower highs – lower lows formation of the last six sessions. Now it has to hold above 25500 zones for momentum to continue towards 25650 then 25800 zones while supports can be seen at 25450 then 25300 zones.

Derivative Outlook:

- Nifty future closed positive with gains of 0.42% at 25696 levels. Positive setup seen in Uno minda, Torrent pharma, KPIT Technologies, BHEL, SAIL, IIFL, Lupin, Larus labs, Power India and Bajaj Finance while weakness in Trent, NCC, Max Healthcare, Fortis, Tata consumer, VBL, Mankind Pharma, HFCL, Samvardhana Motherson and Apollo Hospital.
- On option front, Maximum Call OI is at 25700 then 25600 strike while Maximum Put OI is at 25600 then 25500 strike. Call writing is seen at 25650 then 25700 strike while Put writing is seen at 25600 then 25500 strike. Option data suggests a broader trading range in between 25100 to 26000 zones while an immediate range between 25400 to 25800 levels.

Today's News

- **Dreamfolks Services** - Company will invest Rs11.46 crore to acquire a 50.01% partnership stake in Ten 11 Hospitality LLP, a premium railway lounge operator.
- **Emcure Pharmaceuticals** - Novo Nordisk India has entered into a strategic partnership with Emcure Pharmaceuticals to launch Poviztra®, the second brand of Wegovy® (semaglutide injection 2.4 mg), as part of efforts to widen access to its globally acclaimed anti-obesity therapy.
- **IndusInd Bank** - Company announced the appointment of Mr. Amitabh Kumar Singh as its new Chief Human Resources Officer (CHRO). Mr. Singh brings with him over 28 years of experience in human resources, having spent 21 years with the ICICI Group.
- **Alembic Pharma** - Company announced that it has received final approval from the US FDA for its Abbreviated New Drug Application (ANDA) sumatriptan injection USP. This is Alembic's first drug device combination product. Sumatriptan injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, single-dose autoinjector system, have an estimated market size of US\$ 73 million for twelve months ending September 2025 according to IQVIA.
- **Marksans Pharma's Goa facility clears US FDA inspection with zero observations** - Company announced that its second manufacturing facility in Verna, Goa, successfully completed a current Good Manufacturing Practice (cGMP) inspection conducted by the US Food and Drug Administration (US FDA) with zero Form 483 observations.
- **Adani-JKH Sri Lanka Terminal Posts Strong Volume Growth** - Colombo West International Terminal, backed by Adani Ports and Sri Lanka's John Keells Holdings, is seeing "spectacular" transshipment volume growth, driven in part by economic expansion in India, according to Chief Executive Officer Munish Kanwar. Monthly box volumes have reached an average 100,000 since the terminal began operations in April. Expects year ending March 2026 volumes of about 1 million containers.
- **Government considers Sugar Exports of 1.5 Million Tons** - Government is considering a proposal to allow sugar mills to export 1.5 million tons of the sweetener in 2025-26, as the outlook for an abundant harvest raises concerns about a looming glut.

Global Market Update

- **Asian Market** - Asian stocks rose, supported by a rebound in technology shares following a selloff last week on concerns over lofty valuations. Hopes of a possible end to the longest US government shutdown also lifted sentiment. Japan, Hong Kong, South Korea and Taiwan Index surged 1%.
- **European Market** - European stocks climbed on Monday as hopes for a deal to end the US government shutdown boosted risk. UK, Germany and France Index gained up to 1%.
- **US Data** - Manufacturing PMI.
- **Commodity** - Oil rose 1% to above \$64/bbl as wider markets were lifted by a push to end the US government shutdown, with crude traders also looking toward a data-heavy week that'll yield insights into whether a global glut is forming.

Pivot Table

Co. Name	Close	Low	S2	S1	PP	R1	R2	High
NIFTY 50	25,574	25,504	25,427	25,501	25,577	25,651	25,727	25,653
ADANIENT	2,365	2,364	2,348	2,357	2,372	2,381	2,396	2,388
ADANIPTS	1,444	1,441	1,427	1,435	1,450	1,458	1,473	1,464
APOLLOHOSP	7,534	7,515	7,430	7,482	7,567	7,619	7,705	7,653
ASIANPAINT	2,652	2,611	2,588	2,620	2,643	2,675	2,699	2,667
AXISBANK	1,216	1,216	1,204	1,210	1,221	1,227	1,239	1,233
BAJAJ-AUTO	8,770	8,686	8,612	8,691	8,765	8,844	8,917	8,838
BAJAJFINSV	2,120	2,096	2,084	2,102	2,114	2,133	2,145	2,127
BAJFINANCE	1,087	1,063	1,054	1,070	1,079	1,095	1,104	1,088
BEL	417	414	411	414	417	420	424	420
BHARTIARTL	2,021	1,992	1,977	1,999	2,014	2,035	2,050	2,029
CIPLA	1,508	1,504	1,497	1,502	1,510	1,515	1,522	1,517
COALINDIA	382	376	374	378	380	384	386	382
DRREDDY	1,199	1,195	1,187	1,193	1,201	1,207	1,216	1,210
EICHERMOT	6,895	6,801	6,755	6,825	6,870	6,940	6,985	6,916
ETERNAL	302	301	296	299	304	307	311	309
GRASIM	2,762	2,729	2,700	2,731	2,760	2,791	2,820	2,789
HCLTECH	1,540	1,511	1,499	1,519	1,532	1,553	1,566	1,545
HDFCBANK	985	980	975	980	985	990	996	991
HDFCLIFE	750	749	742	746	753	757	764	760
HINDALCO	785	784	774	779	790	795	806	800
HINDUNILVR	2,409	2,404	2,389	2,399	2,414	2,424	2,439	2,429
ICICIBANK	1,347	1,341	1,337	1,342	1,346	1,351	1,354	1,350
INDIGO	5,586	5,541	5,490	5,538	5,589	5,637	5,688	5,640
INFY	1,515	1,490	1,478	1,497	1,508	1,527	1,538	1,520

Co. Name	Close	Low	S2	S1	PP	R1	R2	High
ITC	406	404	402	404	406	408	409	407
JIOFIN	302	300	298	300	302	303	305	303
JSWSTEEL	1,181	1,172	1,166	1,174	1,179	1,187	1,192	1,185
KOTAKBANK	2,090	2,081	2,068	2,079	2,092	2,103	2,116	2,105
LT	3,917	3,894	3,868	3,893	3,918	3,942	3,968	3,944
M&M	3,666	3,645	3,605	3,635	3,676	3,706	3,746	3,716
MARUTI	15,600	15,380	15,275	15,438	15,542	15,705	15,809	15,647
MAXHEALTH	1,100	1,096	1,068	1,084	1,113	1,129	1,157	1,141
NESTLEIND	1,262	1,260	1,252	1,257	1,265	1,270	1,278	1,273
NTPC	325	324	322	323	326	328	330	328
ONGC	252	250	246	249	252	255	258	256
POWERGRID	268	267	264	266	268	270	272	271
RELIANCE	1,490	1,476	1,463	1,477	1,489	1,502	1,514	1,501
SBILIFE	1,990	1,985	1,965	1,978	1,998	2,010	2,031	2,018
SBIN	951	949	940	945	954	959	968	963
SHRIRAMFIN	821	817	809	815	823	829	837	831
SUNPHARMA	1,693	1,686	1,677	1,685	1,694	1,702	1,711	1,703
TATACONSUM	1,141	1,139	1,116	1,129	1,151	1,164	1,186	1,174
TATASTEEL	182	180	179	180	181	183	184	183
TCS	3,025	2,992	2,966	2,995	3,022	3,051	3,078	3,048
TECHM	1,397	1,384	1,374	1,386	1,395	1,406	1,416	1,404
TITAN	3,800	3,769	3,749	3,775	3,795	3,820	3,840	3,815
TMPV	411	406	403	407	410	414	417	413
TRENT	4,284	4,263	4,058	4,171	4,376	4,488	4,693	4,580
ULTRACEMCO	11,750	11,701	11,591	11,671	11,780	11,860	11,969	11,890
WIPRO	240	237	235	237	239	242	244	242

Siddhartha Khemka
Head – Retail Research

Chandan Taparia, CMT, CFTE
Head – Derivatives & Technical Research

Disclosures:
The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report..

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) “SFO”. As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to “Professional Investors” as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors.” Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. (“MOCMSPL”) (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as “institutional investors” as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore (“SFA”) or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an “institutional investor” nor an “accredited investor”, they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Disclaimer:

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be` suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.